7,8-Dihydroxyflavone

7,8-Dihydroxyflavone

SCHEMBL29374601

O=c1cc(-c2ccccc2)oc2c(O)c(O)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TERT O14746 10/20 1.00
▸ MAPT P10636 7/20 1.00
▸ HPGD P15428 6/20 1.00
▸ KDM4E B2RXH2 6/20 1.00
▸ CYP19A1 P11511 6/20 1.00
▸ ALDH1A1 P00352 5/20 1.00
▸ CYP3A4 P08684 5/20 1.00
▸ HSD17B10 Q99714 5/20 1.00
▸ ALOX15 P16050 4/20 1.00
▸ TP53 P04637 4/20 1.00
▸ MAPK1 P28482 3/20 1.00
▸ MEN1 O00255 2/20 1.00
▸ KMT2A Q03164 2/20 1.00
▸ SMN1; SMN2 Q16637 2/20 1.00
▸ MAOA P21397 2/20 1.00
▸ MAOB P27338 2/20 1.00
▸ IKBKB O14920 1/20 1.00
▸ NTRK2 Q16620 1/20 1.00
▸ CYP2C9 P11712 4/20 0.76
▸ CYP2C19 P33261 4/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
7,8-Dihydroxyflavone SCHEMBL419316 1.00 TERT (1.00) TERTMAPTHPGDKDM4ECYP19A1
7,8-Dihydroxyflavone SCHEMBL21852713 0.98 TERT (0.97) TERTMAPTHPGDKDM4ECYP19A1
7,8-Dihydroxyflavone SCHEMBL29577498 0.94 TERT (0.89) TERTMAPTHPGDKDM4ECYP19A1
SCHEMBL4649959 0.88 TERT (1.00) TERTMAPTHPGDKDM4ECYP19A1
SCHEMBL31322174 0.88 TERT (1.00) TERTMAPTHPGDKDM4ECYP19A1
SCHEMBL4649946 0.87 TERT (1.00) TERTMAPTHPGDKDM4ECYP19A1
SCHEMBL6804531 0.86 TERT (0.81) TERTMAPTHPGDKDM4ECYP19A1
SCHEMBL6615955 0.85 TERT (0.74) TERTMAPTHPGDKDM4ECYP19A1
SCHEMBL31632309 0.85 CYP19A1 (0.74) TERTMAPTHPGDKDM4ECYP19A1
SCHEMBL6618127 0.85 TERT (0.78) TERTMAPTHPGDKDM4ECYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118440896-A Method for protecting RGC-5 high sugar model by 7, 8-DHF 上海市松江区中心医院(上海交通大学附属第一人民医院松江分院) 2024-08-06 — — CN claimed
CN-116981450-A Combination of antidepressants and dextromethorphan for the treatment of neuropsychiatric disorders 安泰赛普生物风投二代有限责任公司 2023-10-31 — — CN claimed
US-20230332103-A1 Methods and Compositions for Generating Human Forebrain Neural Progenitor Cells and for Maturation Thereof to Parvalbumin+ Interneurons TRAILHEAD BIOSYSTEMS INC. 2023-10-19 — — US claimed
CN-117821305-B Bifidobacterium bifidum capable of remarkably improving host BDNF expression quantity and application thereof 江南大学 2026-02-27 — — CN disclosed
CN-119157821-B Double-crosslinked hydrogel and preparation method and application thereof 南方医科大学珠江医院 2025-06-17 — — CN disclosed
CN-119326751-A Application of 7, 8-dihydroxyflavone in preparation of medicines for preventing and treating pulmonary fibrosis 江苏省苏北人民医院 2025-01-21 — — CN disclosed
CN-119157821-A Double-crosslinked hydrogel and preparation method and application thereof 南方医科大学珠江医院 2024-12-20 — — CN disclosed
CN-119112903-A Nanometer preparation for regulating mechanical microenvironment of idiopathic pulmonary fibrosis and preparation method and application thereof 中国药科大学 2024-12-13 — — CN disclosed
CN-119082283-A Novel marker for autism and application thereof 中南大学湘雅二医院 2024-12-06 — — CN disclosed
CN-118440896-A Method for protecting RGC-5 high sugar model by 7, 8-DHF 上海市松江区中心医院(上海交通大学附属第一人民医院松江分院) 2024-08-06 — — CN disclosed
CN-118440896-A Method for protecting RGC-5 high sugar model by 7, 8-DHF 上海市松江区中心医院(上海交通大学附属第一人民医院松江分院) 2024-08-06 — — CN disclosed
CN-109574975-B Crystal form of 7,8-dihydroxyflavone derivative, and preparation method and application thereof 上海博芮健制药有限公司 2023-07-14 — — CN disclosed
CN-116064611-A Non-human animals comprising a humanized TRKB locus 瑞泽恩制药公司 2023-05-05 — — CN disclosed
WO-2023288069-A1 METHODS OF USING SUBSTITUTED FLAVONES FOR TREATING BONE DISORDERS EMORY UNIVERSITY (US) 2023-01-19 — — WO disclosed
CN-111655031-B Non-human animals comprising humanized TRKB loci 瑞泽恩制药公司 2022-11-18 — — CN disclosed
CN-115252600-A Xanthine oxidase inhibitor targeting intestinal flora and application thereof 华南农业大学 2022-11-01 — — CN disclosed
CN-115025075-A New application of FK3 medicine 沈阳药科大学 2022-09-09 — — CN disclosed
CN-114870023-A Slow-release optic nerve protection drug nano synthetic material and preparation method and application thereof 成都市第三人民医院 2022-08-09 — — CN disclosed
CN-114641317-A 7, 8-dihydroxyflavone composite nano biomaterial with high bioavailability as well as preparation method and application thereof 杭州尤美特科技有限公司 2022-06-17 — — CN disclosed
US-20220031641-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING COGNITIVE DYSFUNCTION PHARMATROPHIX, INC. 2022-02-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220031641-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING COGNITIVE DYSFUNCTION CHRM3, CHAT, CHRM5 TERT 2814/4885MAPT 451/4885HPGD 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback